today third discusses Thank in Good you, and will to our Nicole. our us Paul thank quarter results. for review third quarter results call before on financial and you the from afternoon highlights joining XXXX I outlook our discuss the detail.
The third results achieved cost driving flow, to ongoing specifically, both the record a once year-over-year per a the We very another was quarterly and $XX.X again record improvements margin generally growth strong us. for strong for and revenue million. once the and revenue, a volume achieved test. GAAP quarter again gross test XX% profitability the while quarter in We cash
XX,XXX. tests increased record to year-over-year of a high Billable XXX% new
to ASP Our the essentially quarter second of $XXX XXXX. was compared flat
excluding margin, of test per improve, test. record per to cost further gross compensation our improved stock-based low a to our While continue per costs increased test $XXX
point Non-GAAP point percentage quarter up quarter X third up last gross in the X year approximately XX% margin third was from approximately percentage and the sequentially.
third GAAP the share quarter, $X.XX per income quarter. income $X.XX adjustable million Non-GAAP was was $X.X positive earnings was non-GAAP million. a in $X.X third EBITDA was and and the in
and ramp driving given how for the consistent Genetics, growth. recent it in our record third test quarter we the market we with the The traction into was -- is to are our more seen have another gaining offer Fulgent insight quarter demonstrating mix
hereditary have for seeing and on reproductive for oncology our health are we cancer side, both business, we our critical core business. the our Especially increasing test our strong First, panels. demand oncology demand seen
growing rapid quality And is time our as competitive become as turnaround result, a in a sector. growth driving of oncology as to volume. well superior are Our portion pricing notable revenue the
we Second, and we service companies are on seeing the increasing the partners, our have channel therapeutic business genomics pharmaceutical and institutions various development. with established our for demand focus discoveries sequencing for from the the
Third, we logistic paying with partnerships the laboratories. are cash certifying commercial several genomic
have We from seen results these partnerships. early
We have growth. additional fields provided for the recent
increase we growth into growth in pleased of recent look are have at ramp our expectations in start ahead. our the that optimistic most remain our remain sure for the and this the [ph] recent year, same expensed but of We ahead the we with growth. expectations balanced has that sustainability volumes translated have we business time, the results at make as seeing focus we quarters experienced, Though and
in the fluctuation spreads over To as anticipate business expand and run. we that diversify long short our the the term demand end, our
stability core and confident We the investments consistency. in made additional our business clinical part are increased contribute driving of revenues, time, that we will have our sales, business over large offset a
be people has to As to in the increased made activities volume investment automation to computer able bioinformatics, years. and the artificial [Indiscernible] have rapid science, is recent I intelligence, ramped, biometric, due our we the manage in
the our and a we and improvement due lot in automation. growth of Our for this lab have financially business [ph] envisioning still margin bottom line. volumes. have the that test, has strong. of our see notably, is volume, capacity in per And have additional out-driven increase can in continued a we Most scale more cost more to benefit to With we become and see the efficiently our this
with market. the industry, in We a among we the lowest that have the capability the are flexibility and wider confident drive cost to
to treatment expertise in the technology our treatment the a core Parkinson example help and expertise An for done standpoint. is we develop areas and position rare leveraging competitive to even establish efficient Aside this findings, experience the is our data market from inquiry guideline this the the pediatric, for our interpretation Foundation well the an have certain disease has to with a of disease. of a which the of provided Years advantage, as scientific traditional greater from work more platform disease. the provides and edge which solutions financial as
enables only our also In addition, a investment. our approach, our we quality us software to libraries or tests with existing provided the proprietary see a introduce to not and ability each the maintain test This financial minimal [Indiscernible] quickly, of largest into but develop has market no a and introduce need overheads. to engineers one additional with both the where to -- opportunity test to of with from
from testing companies, the financial, technology that result operational in Further, these genetic market. companies testing give us this to the We perform us unlike distinguishes, technological in-house platform genetic believe many all and [Indiscernible]. tests all ability our need other differentiate
of end, launched patient testing Picture everyday genetic which that and consumer we announced a Genetic, recently testing offers offering, To consumer. a to new a level a initiative believe capabilities genetic we is
about to a We them able decision more enable informative bring to to health. pleased are clinical to greater be directly make testing consumers genetic to their results
at-home with Picture because a need counseling different record from they genetic it. offerings Genetics those is clinical support genetic who results [Indiscernible] testing for along provide actionable
We offering three different tests the also line. are to product Picture Genetic
Parenting, Wellness and the Newborn.
Wellness available year. will Our tests be available Newborn now, online while are later this Parenting and the
in immediate to opportunity at the see to We but test reach the time expect more term. from directly, this are do we meaningful same about consumers contribution revenue excited this
consumers structure service that affordable be at low Our and price. [Indiscernible] the enable to an us sustainable cost to provide this
test with in driving growth. success incremental remain We approach see the to have top offerings have investments expanding opportunity and growth line we legal and to paying overhead. continue our we in have Overall, spending, made to our disciplined off
a and in we area third for now continued of investment, research test invest new health, In have available development have reproductive to test. announced which the consumers. In we for that enhance our to is quarter
the to and embryos during control test abnormal in which them have has an of transfer. launch the the enable woman process PGT-A We are a and IVF process. pleased the over to selections embryo test more a announce the doing a that IVF potential identifies This
Ultimately have markets, the the very we in notable as XX of had launched our for increase has inflections and have words we vertical summary, our with quarter growth. last which strong the a fuelled months healthy pregnancy. seen In new business. probability another numerous tests In growth we
position to quarter. over to outlook we ahead, details on in XXXX. about CFO our to performance provide and confident full I optimistic like an Looking also will financial call our financial for And our turn he the third year market Kim, now our opportunity. remain Paul update the on the and would provide Paul?
